Integra LifeSciences (NASDAQ:IART) Rating Lowered to Buy at Wall Street Zen

Integra LifeSciences (NASDAQ:IART) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

IART has been the topic of several other research reports. Wells Fargo & Company upped their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Citigroup reissued a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Truist Financial lifted their price target on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday. Finally, BMO Capital Markets assumed coverage on Integra LifeSciences in a report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $19.25 on Friday. The business has a 50-day simple moving average of $16.91 and a 200 day simple moving average of $13.08. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.26. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -2.98, a PEG ratio of 1.33 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter in the prior year, the company earned $0.41 earnings per share. The company’s quarterly revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, research analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in IART. Osaic Holdings Inc. increased its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares during the period. State of Tennessee Department of Treasury grew its position in Integra LifeSciences by 7.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock worth $332,000 after acquiring an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the period. Capital Fund Management S.A. grew its holdings in shares of Integra LifeSciences by 5.7% in the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter worth $25,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.